LON:AZN - AstraZeneca Share Price, Forecast & News

AstraZeneca's stock was trading at GBX 6,955 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZN shares have decreased by 2.2% and is now trading at GBX 6,805. View which stocks have been mosted impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Wednesday, April 29th 2020. View our earnings forecast for AstraZeneca.

AstraZeneca announced a dividend on Friday, February 14th. Shareholders of record on Thursday, February 27th will be given a dividend of GBX 146.40 per share on Monday, March 30th. This represents a dividend yield of 1.92%. The ex-dividend date is Thursday, February 27th. This is a positive change from AstraZeneca's previous dividend of $71.90. The official announcement can be accessed at this link. View AstraZeneca's dividend history.

16 brokerages have issued twelve-month price objectives for AstraZeneca's shares. Their forecasts range from GBX 6,000 to £100. On average, they anticipate AstraZeneca's share price to reach GBX 7,862.14 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View analysts' price targets for AstraZeneca.

News stories about AZN stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutAstraZeneca.

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Vectura Group (VEC), Opthea (OPT), Mayne Pharma Group (MYX), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), NanoViricides (NNVC), Vita Life Sciences (VLS) and Recce Pharmaceuticals (RCE).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Vodafone Group (VOD), Hain Celestial Group (HAIN), NVIDIA (NVDA), National Retail Properties (NNN), BP (BP), Royal Dutch Shell (RDSB), Marks and Spencer Group (MKS), Encana (ECA) and Philip Morris International (PM).

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AZN stock can currently be purchased for approximately GBX 6,805.

AstraZeneca has a market capitalization of £89.29 billion and generates £24.38 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe. View additional information about AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.